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Colonization and infection with vancomycin-
resistant enterococci (VRE) are emerging world-
wide. In Europe, agricultural use of the glyco-
peptide growth promoter avoparcin has been
implicated in the emergence of vanA VRE in the
food chain (1), and fecal colonization rates of 2%-
28% have been reported in some communities (2,3).
In the United States, where avoparcin is not
used, both vanA and vanB VRE strains appear to
be largely nosocomially spread, with fecal VRE
colonization rare in nonhospitalized patients (4,5).
By contrast, in Australia, where avoparcin has
been used widely (10,000 kg/year) in agriculture
for many years (6) and the per capita consump-
tion of antibiotics is one of the highest in the
world (7), VRE (mostly vanB [8]) has only recently
emerged as an important nosocomial pathogen.
We assessed the rate of fecal VRE colonization in
a population of healthy Australians.
The Study
In mid-1997, fecal specimens from 1,085
healthy volunteers were collected and frozen at
-70°C as baseline specimens for a water quality
study in Melbourne, Australia. These previously
described (9) volunteers were from 294 families
with young children who lived in a lower- to
middle-class suburb. They were specifically
chosen because they were representative of
young Australian families in eating habits and
medical care. Thus, the elderly, the unmarried,
and the very poor were not represented. Study
participants had no history of diarrhea or
antibiotic use at the time of specimen collection.
For VRE screening, frozen samples were
thawed and spread onto enterococcosel agar
(BBL Microbiology Systems, Cockeysville, MD)
containing 6 µg/mL vancomycin and incubating
at 35°C for 48-72 hours. Each sample was also
incubated in enterococcosel broth (BBL) without
vancomycin for 48 hours, before being spread
onto enterococcosel agar containing 6 µg/mL
vancomycin. From esculin-positive colonies,
three of each morphologic appearance were
selected from the direct agar and the subcultured
enterococcosel broth cultures of each specimen
and provisionally identified as either Enterococ-
cus faecium or E. faecalis by routine criteria
(gram-positive cocci, L-pyrrolidonyl-ß-naphthy-
lamide hydrolase–positive, nonmotile, catalase-
negative, and pigment-negative) (10,11). All
isolates fulfilling these criteria were assessed
for susceptibility to vancomycin and teicoplanin
by the E-test method (AB Biodisk, Dalvagen,
Sweden). Isolates with an MIC to vancomycin
>2 µg/mL were analyzed for the presence of
vanA, B, C1, or C2/3 genes by polymerase chain
reaction (8); if vanA- or vanB-positive, they were
then confirmed as either E. faecium or E. faecalis
by automated biochemical analysis (BioMerieux
Vitek Inc., MO) and by polymerase chain
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reaction, and were assessed by pulsed-field gel
electrophoresis (PFGE) (8,12,13).
To be certain that this analysis of frozen
specimens was a valid assessment of the rate of
fecal VRE carriage in this population, two
additional studies were conducted. First, to
verify that -70°C storage did not affect the overall
recovery of enterococci, a randomly selected
subset of 112 of the 1,085 specimens were
cultured on enterococcosel agar (BBL) without
antibiotic and assessed for enterococci by routine
identification techniques (10,11). In addition, to
assess whether -70°C storage could selectively
impair recovery of VRE, fresh fecal specimens
were spiked with concentrations (104-108/mL) of
isolates of E. faecalis (vanA, n=1, vanB, n=2)
or E. faecium (vanA, n=2; vanB, n=2), then
stored at -70°C for 2 weeks before being thawed
and cultured.
Results
Enterococci were identified in 106 of the
subset of 112 specimens, a rate consistent with
previous reports (14). VRE were also consistently
recovered from our frozen spiked specimens.
These findings suggest that -70°C storage of
specimens does not affect the recovery of
enterococci in general, or VRE in particular.
In the community study, VRE was isolated
from 2 (0.2%) of the 1,085 (95% confidence
intervals 0%-0.4%) specimens. Both isolates were
vanB E. faecium and were detected in both agar
and broth cultures. E-test MIC results at 24
hours for both isolates were 12 µg/mL for
vancomycin and 0.125 µg/mL for teicoplanin.
Although they were identical by PFGE, they
displayed a PFGE pattern that is  uncommon
among VRE isolates from Melbourne hospitals.
The two participants who were vanB E. faecium
positive were not related. One was a 34-year-old
man and the other a 30-year-old woman; both
were married, and each had two children. None of
the other family members had detectable fecal
VRE colonization. The man had a history of
stable ulcerative colitis and was receiving
sulfasalazine.
Conclusions
This study suggests that fecal colonization
with VRE is present but uncommon in  Australia.
Despite widespread agricultural use of avoparcin
and high community rates of antibiotic use, vanA
E. faecium was not identified. vanB E. faecium,
which is the most common clinical VRE strain in
Australia (8) and whose nosocomial transmission
remains a concern (15), was identified in healthy
Australians.
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